SCHEMBL651926

SCHEMBL651926

CCCC(CC)(C(=O)OCC)P(=O)(O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 7/20 0.44
CYP4F2 P78329 2/20 0.40
CYP4A11 Q02928 2/20 0.40
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
PKM P14618 2/20 0.36
THRB P10828 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
MAPT P10636 1/20 0.36
ATM Q13315 1/20 0.36
HTT P42858 1/20 0.35
MMP8 P22894 1/20 0.34
ALDH1A1 P00352 2/20 0.34
LMNA P02545 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
GGPS1 O95749 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2240802 0.92 FDPS (0.43) FDPSCYP4F2CYP4A11MEN1KMT2A
SCHEMBL2237636 0.89 FDPS (0.43) FDPSCYP4F2CYP4A11MEN1KMT2A
SCHEMBL16048 0.88 CYP4F2 (0.40) CYP4F2CYP4A11MEN1KMT2APKM
SCHEMBL18759662 0.88 CYP4F2 (0.40) CYP4F2CYP4A11MEN1KMT2APKM
SCHEMBL2043413 0.87 FDPS (0.42) FDPSGGPS1
SCHEMBL413276 0.86 CYP4F2 (0.39) CYP4F2CYP4A11MEN1KMT2APKM
SCHEMBL19278938 0.86 CYP4F2 (0.39) CYP4F2CYP4A11MEN1KMT2APKM
SCHEMBL2051228 0.86 MEN1 (0.49) FDPSCYP4F2CYP4A11MEN1KMT2A
SCHEMBL2046239 0.86 MEN1 (0.49) FDPSCYP4F2CYP4A11MEN1KMT2A
SCHEMBL2043818 0.86 MEN1 (0.49) FDPSCYP4F2CYP4A11MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 697 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115536719-A Synthetic method of high-purity plant source 7-ketolithocholic acid 江苏佳尔科药业集团股份有限公司 2022-12-30 CN claimed
CN-115246867-A Method for synthesizing 7-ketolithocholic acid by taking BA as raw material 江苏佳尔科药业集团股份有限公司 2022-10-28 CN claimed
WO-2021109791-A1 METHOD FOR SYNTHESIZING URSODEOXYCHOLIC ACID USING BA AS RAW MATERIAL 江苏佳尔科药业集团股份有限公司 2021-06-10 WO claimed
EP-1017687-A4 PROCESS OF MAKING 3-ARYLOXY, 4-ARYL FURAN-2-ONES USEFUL AS INHIBITORS OF COX-2 MERCK & CO INC (US) 2001-10-31 EP claimed
EP-1017687-A1 PROCESS OF MAKING 3-ARYLOXY, 4-ARYL FURAN-2-ONES USEFUL AS INHIBITORS OF COX-2 Merck & Co., Inc. (US) 2000-07-12 EP claimed
WO-1999015513-A1 PROCESS OF MAKING 3-ARYLOXY, 4-ARYL FURAN-2-ONES USEFUL AS INHIBITORS OF COX-2 MERCK & CO., INC. (US) 1999-04-01 WO claimed
JP-60152556-A None JP disclosed
US-12637430-B2 Interleukin-17 (IL-17) inhibitors HITGEN INC. (CN) 2026-05-26 US disclosed
CN-122010730-A Preparation method of key intermediate of Lutrepah 重庆常捷医药有限公司 2026-05-12 CN disclosed
US-12492356-B2 Oxa-sandalwood-type fragrance compounds SYMRISE AG (DE) 2025-12-09 US disclosed
EP-4177249-B1 IMMUNOMODULATOR HITGEN INC (CN) 2025-12-03 EP disclosed
US-20250313557-A1 IMIDAZO[4,5-C]PYRIDINE DERIVATIVE COMPOUNDS AS TLR7/8 MODULATORS LIGACHEM BIOSCIENCES INC. (KR) 2025-10-09 US disclosed
US-12410113-B2 Sandalwood-type fragrance compounds SYMRISE AG (DE) 2025-09-09 US disclosed
US-4376124-A Method for modulating the immune response with dibenzocycloheptenylidenes AMERICAN HOME PRODUCTS CORPORATION (US) 1983-03-08 US disclosed
WO-1981002519-A1 METHOD FOR TREATING INFLAMMATION AMERICAN HOME PROD (US) 1981-09-17 WO disclosed
EP-0035903-A1 Dibenzocycloheptenylidenes and their use in pharmaceutical compositions AMERICAN HOME PRODUCTS CORPORATION (US) 1981-09-16 EP disclosed
US-4267192-A BY ADMINISTERING AN UNSATURATED DIBENZOCYCLOHEPTENE ACID OR ESTER COMPOUND AMERICAN HOME PRODUCTS CORPORATION (US) 1981-05-12 US disclosed
US-4265769-A CORROSION RESISTANCE, ANTISCALING AGENTS CIBA-GEIGY CORPORATION (US) 1981-05-05 US disclosed
US-4208344-A CORROSION RESISTANCE, ANTISCALING AGENTS CIBA-GEIGY CORPORATION (US) 1980-06-17 US disclosed
US-4136197-A HYPOGLYCAEMICALLY AND HYPOLIPIDAEMICALLY EFFECTIVE N-SUBSTITUTED CARBOXYLIC ACID AMIDES BOEHRINGER MANNHEIM GMBH (DE) 1979-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12410113-B2 Sandalwood-type fragrance compounds FDFT1, FAAH2, FAAH FDPS 14/4885CYP4F2 530/4885CYP4A11 206/4885
US-12637430-B2 Interleukin-17 (IL-17) inhibitors IL17A, IL2, IL23R FDPS 2753/4885CYP4F2 383/4885CYP4A11 59/4885
US-12492356-B2 Oxa-sandalwood-type fragrance compounds FDFT1, FAAH2, ALDH1A1 FDPS 54/4885CYP4F2 689/4885CYP4A11 484/4885
US-20250313557-A1 IMIDAZO[4,5-C]PYRIDINE DERIVATIVE COMPOUNDS AS TLR7/8 MODULATORS TLR7, TLR8, TLR3 FDPS 3974/4885CYP4F2 3484/4885CYP4A11 2115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.